Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage 1 . We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57-81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.
. As recognition of neoantigens that result from somatic non-synonymous mutations is associated with improved clinical responses to anti-PD-1 and anti-PD-L1 therapy [3] [4] [5] [6] , we hypothesized that patients with DM might respond well to anti-PD-1 or anti-PD-L1 therapies, owing to their high mutational load.
We conducted a retrospective review of the pathology reports from 1,058 patients with advanced melanoma treated with anti-PD-1 or anti-PD-L1 immunotherapies between 2011 and 2016 at ten international sites with high-volume melanoma clinical trials. We identified 60 patients with advanced, unresectable DM who received PD-1 or PD-L1 blockade therapy (Extended Data Tables 1, 2) . Thirty-five patients (58%) had extra-pulmonary visceral metastases or elevated lactate dehydrogenase (M1c disease), which are recognized makers of poor prognosis 7 . Local pathologists reported histological subclassification into pure (n = 25), mixed (n = 30) or indeterminate (n = 5) DM subtypes 8 . All cases had the distinctive diagnostic features of DM with abundant connective tissue surrounding the tumour cells, which can be highlighted by Masson's trichrome stain (examples in Fig. 1a , with the collagenous stroma stained in blue). Central review of haematoxylin and eosin-stained tissue from 34 cases by two pathologists revealed that 65% of cases had a substantial fibrous stroma (graded 2-3), and that 63% of cases had lymphoid aggregates within the tumour and/or at the tumour stromal interface (graded 1-3) (Supplementary Table 1 ). Forty-two patients (70%) had progressed after prior systemic treatment, most frequently with the cytotoxic T lymphocyte antigen-4 (CTLA-4) blocking antibody ipilimumab (Extended Data Table 1 and  Supplementary Table 1 ). The most frequently administered anti-PD-1 or anti-PD-L1 drug was pembrolizumab (in forty-five patients (75%)), while eight (13%) received nivolumab, three (5%) the anti-PD-L1 antibody BMS-936559, and an additional three (5%) received a combination of nivolumab or pembrolizumab with ipilimumab.
With a median follow up of 22 months, 42 out of the 60 patients (70%, 95% Clopper-Pearson confidence interval of 57-81%) had an objective response by RECIST 1.1 criteria (Fig. 1b, c) . This included 19 (32%) complete responses and 23 (38%) partial responses; nine patients with a partial response eventually showed tumour progression but none of the patients with complete response did. When the four patients treated with a combination of anti-PD1 drugs and ipilimumab were excluded, responses were seen in 38 out of 56 (68%) patients. Three patients with isolated progression (including two who had a partial response) underwent surgery and subsequently had no evidence of melanoma with ongoing follow up for more than 1.8, 5.2, and 5.3 years. Median progression-free survival and overall survival have not been reached, with an estimated two-year overall survival of 74% (95% confidence interval 60-84%) (Extended Data Fig. 1a, b) . For patients censored in the Kaplan-Meier curve, median follow-up was 27 months or more. There were no statistically significant differences in either objective response rate (65% versus 70%), or overall survival between patients with the two histological subtypes of DM (pure or mixed). There was also no difference in objective responses based on degree of fibrosis or presence of lymphoid aggregates (Supplementary Table 1) .
Whole-exome sequencing from 17 cases in our DM cohort revealed more than 82% C> T transitions as part of a strong signature of ultraviolet light-induced DNA damage that is common to cutaneous melanoma 1,9 (Extended Data Fig. 2a, b) . There was no difference in mutational load between locally advanced and metastatic lesions Letter reSeArCH (Extended Data Fig. 3a) . Mutations in NF1 in the absence of BRAF or RAS family hotspot mutations were the most common driving genetic event (82.4%, 14 of 17 samples), along with enrichment for loss-offunction mutations in TP53 and ARID2 (Fig. 2a, Extended Data Fig. 3b ), similar to previously published series of DM 1, 10 . These features are also characteristic of NF1 subtype melanoma, which comprises 8-12% of cutaneous melanoma cases in large cohorts and has more than double the mutational load of the NRAS, BRAF or triple wildtype subtypes [11] [12] [13] . Our DM series had similar mutational load to NF1 subtype cases (regardless of histological classification) in a combined Desmoplastic melanoma All melanoma 14, 15 All melanoma 13 
NF1
Response to anti-PD- Figure 2 | High mutational load and similarity to NF1 subtype in DM. a, Top bar graph represents mutational load. Tiling plot shows mutations in a given gene (rows) per sample (columns). In the tiling plot, top line represents response, as either primary resistance or progressive disease (red; n = 5), or response (partial or complete response and stable disease for more than 12 months; dark blue; n = 12). Colour indicates mutation type, with truncating mutations (frameshift, nonsense, splice-site) in red, missense in green. Darker colour intensity indicates potentially homozygous mutations, with variant allele frequency (VAF) more than 1.5 times the sample median. Asterisk, biopsy from responding lesion despite a mixed response and eventual progression. Circle, patient showed no evidence of disease for more than 1 year after surgical resection of a progressing lesion. b, Non-synonymous mutations determined by whole-exome sequencing from the current DM cohort, two pooled studies of anti-PD1 treated cutaneous melanoma 14, 15 and TCGA data 13 . Each cohort is split by driver mutation subtype. Colour indicates PD1 blockade therapy response (red, progression; blue, response), and shape represents the subtype of DM (pure versus mixed). In the box plots, line shows median, box shows 25th and 75th percentiles, whiskers show highest and lowest values within 1.5 times interquartile range. Two-sided Wilcoxon Mann-Whitney rank sum test.
Letter reSeArCH series from two reports of patients with anti-PD-1-treated advanced melanoma 14, 15 and in data from the Cancer Genome Atlas (TCGA) 13 . In all three series, NF1 mutated cases had a substantially greater mutational load than the non-NF1 subtypes, but there was no difference in response to PD-1 blockade (Fig. 2b) . Patients with DM that did not respond (n = 5) showed no difference in mutational load compared with patients that did respond (rank sum P = 0.87, Fig. 2b ). This is consistent with the findings of two previous anti-PD-1-treated cohorts 14, 15 but not with data from patients with melanoma treated with anti-CTLA4 16 (Extended Data Fig. 3c ) or patients with lung and bladder cancer treated with anti-PD-1 or anti-PD-L1 therapy 3, 6 . We did not find any genes that were mutated more frequently in patients with DM with or without response to therapy (Extended Data Fig. 4a ), including when performing specific analyses for potential detrimental mutations in the interferon receptor pathway or B2M that may result in innate or acquired resistance to anti-PD-1 therapy 14, 17 (Extended Data Fig. 4b ). We evaluated whether the presence of CD8 + T cells and PD-L1 in DM was associated with response to anti-PD1 or anti-PD-L1 therapy 18 ,19 using 19 available pre-treatment DM tumour biopsies compared to 13 non-DM samples (seven with a complete or partial response, six with progressive disease) using digital quantitative immunohistochemistry (IHC). We used S100 expression to define the invasive tumour margin (stromal-tumour edge) and inside tumour parenchyma (tumour centre) (examples in Extended Data Fig. 5f .). Overall, biopsies from patients with DM had a notably higher percentage of PD-L1 positive cells in the tumour parenchyma than non-DM cases (P = 0.04, Fig. 3a) , confirming the same finding from primary DM lesions 20 . There were no significant differences in the density of CD8 + cells in the tumour parenchyma, or of CD8 + and PD-L1 + cells in the invasive margin (P = 0.12, P = 0.41 and P = 0.16, respectively; Fig. 3b-d) . Consistent with previous observations 18 , the strongest correlation with clinical benefit (defined as having a complete or partial response, or prolonged stable disease for more than 12 months) was baseline density of CD8 + T cells in the invasive margin in non-DM melanoma (P = 0.002, Extended Data Fig. 6a-d) .
In DM samples, PD-L1 expression in the tumour parenchyma was significantly associated with CD8 density (P = 0.007) and PD-L1 expression in the invasive margin (P = 0.0003), but not with CD8 density inside the tumour parenchyma (P = 0.15, Extended Data Fig. 7) . Similarly, PD-L1 expression in the invasive margin was significantly associated with CD8 density in the invasive margin (P = 0.0003), CD8 density in the tumour parenchyma (P = 0.04), and PD-L1 expression in the tumour parenchyma (P = 0.0003). Among DM cases for which we had exome sequencing, we did not detect many of the genetic mechanisms reported to cause constitutive PD-L1 expression, including amplification of the PD-L1-PD-L2-JAK2 (PDJ) locus, mutations or amplification of MYC or EGFR, or disruption of CDK5 [21] [22] [23] [24] . The 3′ UTR of CD274 (encoding PD-L1) was not well captured in our exome sequencing, and disruption could not be assessed 25 . Therefore, the higher PD-L1 expression in DM is likely to result from a reactive response to CD8 + T cell infiltrates that reflect adaptive immune resistance 26 . We noted five distinct patterns of CD8
+ cell infiltration and PD-L1 expression in the invasive margin and tumour parenchyma; most patients who responded to therapy had one of the three patterns characterized by high CD8 + T cells (twelve out of fourteen with DM and six out of seven with non-DM; Extended Data Fig. 5a-e) . Patients without a tumour response tended to have low CD8
+ cells regardless of the status of PD-L1 (Extended Data Fig. 5g) , although a small number of patients (two out of nine) whose tumours had low baseline CD8 + infiltrates responded to therapy. We integrated the data regarding CD8 and PD-L1 expression in biopsies with response and mutational load, allowing cases of DM and non-DM to self-organize on the basis of these data (Extended Data Fig. 8a and b) . CD8 and PD-L1 levels did not differ between cases with pure or mixed DM histology (Extended Data  Fig. 8b ). Biopsies in which the invasive margin showed higher CD8 + density clustered together, usually with higher PD-L1 expression both in the tumour and in the invasive margin, and were enriched in patients with an objective tumour response. Mutational load, which was relatively high in all these cases, did not cluster with any particular pattern of CD8 or PD-L1 expression, or with response to therapy.
Dense collagenous stroma as found in DM has been thought to be an important limitation for immune infiltration, as has been described for pancreatic cancer 27 . However, our data challenge this notion, as there are pre-existing T cell infiltrates in the invasive edge of DM lesions, and DMs show a much higher response rate to anti-PD1 therapy than any other subtype of melanoma. The response rate of 70% in DM, together with relapsed Hodgkin's disease and Merkel cell carcinomas 21, 28 , is among the highest responses to single agent PD-1 blockade therapy in any pathologically defined cancer. Our data suggest that DM, and probably the non-DM NF1 subtype arising from sun-exposed areas, have a high response rate to PD-1 blockade therapy because they have a more dynamic pre-existing adaptive immune response.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
MethOdS
Analysis of clinical data. To conduct this retrospective analysis, records of 1,058 patients with advanced melanoma treated with anti-PD-1 or anti-PD-L1 therapy were reviewed across ten institutions to identify those with a diagnosis of DM. Each institution conducted its own search to find patients who fit these criteria. The study was conducted under Institutional Review Board approval at each centre and complied with all relevant ethical regulations. All patients had signed a local written informed consent form for research analyses. Consent to obtain photographs was obtained. No statistical methods were used to predetermine sample size. The experiments were not randomized. Immunohistochemistry (IHC) analyses. Patients were selected for IHC analysis if they had adequate pre-treatment tumour samples and had signed a local written informed consent form for research analyses. Tumour samples were obtained from eight institutions. Slides cut from frozen or FFPE tissue samples were stained with haematoxylin and eosin, Masson's trichrome stain, or anti-S100, anti-CD8, and anti-PD-L1 at the UCLA Anatomic Pathology Immunohistochemistry and Histology Laboratory (CLIA-certified). Antibodies used included rabbit polyclonal S100 (DAKO, 1:1,000 dilution, low pH retrieval), CD8 clone C8/144B (Dako, 1:100, low pH retrieval), and PD-L1 (Spring Biosciences, Sp142, 1:200, high pH retrieval). IHC was performed on Leica Bond III autostainer using Bond ancillary reagents and a Refine Polymer Detection system. Slides were examined for the presence of CD8 and PD-L1 within the tumour parenchyma and the connective tissue surrounding the tumour (invasive margin). We defined the invasive margin (or leading edge) as the interfaces between individual tumour bundles and the fibrotic regions, as opposed to the intra-tumour staining, which is within the capsule of individual tumours. All slides were scanned at an absolute magnification of × 200 (resolution of 0.5 μ m per pixel). An algorithm was designed based on pattern recognition that quantified immune cells within S100-positive areas (tumour) and S100-negative areas (invasive margin). The algorithm calculated the percentage cellularity (% positive cells/all nucleated cells) using the Halo platform (Indica Labs). This analysis system was not able to differentiate between tumour cell or infiltrating immune cell PD-L1 staining 30 . Immunohistochemical variables were compared between biopsies of patients who responded or progressed on treatement using the Wilcoxon Mann-Whitney test. Lymphocytic infiltrate and fibrosis analysis. We analysed available pathological samples from 34 cases to define their lymphoid inflammation and degree of fibrosis. There is no quantitative measure for these readouts, so we used a semiquantitative pathological assessment. Examples of each grade were circulated to pathology reviewers to ensure reproducibility. The investigators were not blinded to allocation during experiments and outcome assessment. When available, metastatic lesions were graded by the same schema as primary samples, as not all patients had primary tumour samples available for quantification. The hallmark of lymphoid infiltration in DM is the presence of lymphoid nodules within and occasionally surrounding the tumour. Therefore, we developed the grading schema below to describe the location of these nodules within the tumours: 0: no lymphoid aggregates 1: lymphoid aggregates within tumour 2: lymphoid aggregates at tumour-stroma interface 3: lymphoid aggregates within tumour and at tumour-stroma interface A grading schema was also developed to describe the degree of fibrosis in tumours: 0: no significant stroma separates tumour cells 1: mild increase in fibroblasts and/or myxoid stroma separates tumour cells 2: moderate increase in fibroblasts and/or myxoid stroma separates tumour cells 3: tumour cells separated by abundant fibromyxoid stroma Genetic analyses. In brief, whole-exome sequencing was performed at the UCLA Clinical Microarray Core using the Roche Nimblegen SeqCap EZ Human Exome Library v3.0 targeting 65 Mb of genome. Mutation calling was performed as previously described 14, 17 . Out of 22 biopsies of DM sequenced, 17 cases (3 complete responses, 8 partial responses, 1 stable disease, 5 progressive disease) could be analysed by meeting quality control criteria for minimum coverage (50× tumour, 30× normal), tumour content (10%), and effective depth (coverage multiplied by tumour content > 12× , representing > 80% probability to detect heterozygous mutations with at least four reads). These were compared with exome sequencing from the TCGA 13 , a prior DM cohort 1 , and two anti-PD-1 monotherapy-treated cohorts, one from our group 14 with 23 cases which included a mix of responders and non-responders, and the second a subset of 30 patients after non-response to CTLA-4 15 . From that cohort to include one sample per patient, we excluded ontreatment samples in the setting of response; then we selected the biopsy with the highest tumour purity, regardless of time point, since most patients with more than one biopsy had < 10% variance in their mutational loads. Response was defined as CR, PR, or SD for > 12 months by RECIST1.1 in both cohorts. Mutation calling methods between cohorts all used MuTect at their core, and only non-synonymous mutations (Nonsense, Missense, Splice_Site, Frameshift indels, In-frame indels, Start_Codon indels or SNPs, and Stoploss/Nonstop variants) were assessed to minimize differences between exon-capture kits. An additional filter was applied to all data sets to exclude mutations at sites of known germline variation with an allele frequency > 0.0005 in the Exome Aggregation Consortium (ExAC) database v0.3.1. Tumour purity was estimated by Sequenza, or as 2 × median variant allele frequency if less than 30%. Loss-of-function burden was determined using the LOF SIgRank algorithm 1 , with the simulation run for 1,000 iterations and synonymous mutations for background mutation rate defined as silent, 3′ UTR, 5′ UTR, or exon-flanking intronic mutations. Single nucleotide variants and their flanking contexts were analysed for mutation signatures for the DM and UCLA non-DM 14 cohorts together using a published tool 9 . Statistical analyses. The Kaplan-Meier method and Greenwood's formula were used to estimate survival probabilities (survival rates and overall survival) and the corresponding 95% confidence intervals (CIs). Progression-free survival was defined from start of treatment to disease progression or death from any cause. Overall survival was defined from start of treatment to death from any cause. The objective response rate was reported as proportion along with Clopper-Pearson exact CIs. The chi-square and Fisher's exact tests were used to test for differences between groups for categorical variables. The Wilcoxon Mann-Whitney rank sum test was used to compare mutation rates between groups. Statistical analyses of the pathological data were performed using GraphPad Prism and mutation data using R v3.2.5. All tests were two-sided; P values < 0.05 were considered statistically significant. Data availability. Whole-exome sequencing data has been deposited in the National Center for Biotechnology Information (NCBI) dbGaP (https://www.ncbi. nlm.nih.gov/gap) with accession number phs001469. All other data are available from the authors on reasonable request. Records of 1058 pts with advanced melanoma treated with anti-PD1/PDL1 therapy were reviewed across ten institutions to identify those with a diagnosis of DM. Each institution conducted its own search to find patients who fit these criteria.
Letter reSeArCH

Data exclusions
Describe any data exclusions. From the 60 identified advanced DM patients, those without tumor tissue available were not included in the IHC or WES analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
The IHC analyses were replicated twice. The WES was done once.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Samples were not randomized as this was not relevant to this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not relevant for this study, as clinical data and tumor tissue was from patients all known to have desmoplastic melanoma. However, personnel who performed the IHC staining and sequencing of the tumor tissue did not know the clinical data (response, survival, etc) of the patients.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
